Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus

a technology of gestational diabetes and exendins, which is applied in the direction of peptide/protein ingredients, extracellular fluid disorders, metabolic disorders, etc., can solve the problems of increasing the incidence of hypoglycemia, and achieve the effect of prolonging the effect of blood glucos

Inactive Publication Date: 2008-05-29
ASTRAZENECA PHARMA LP
View PDF16 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about using exendins and exendin agonists to treat gestational diabetes mellitus. These compounds have been found to have beneficial effects on blood glucose levels without causing weight gain or hypoglycemia. Exendin agonists include exendin-3 and exendin-4, which can be administered to patients through injection. The invention provides a therapeutic method for treating gestational diabetes by administering an exendin or exendin agonist to a patient in need of treatment.

Problems solved by technology

Additionally, in animal and human studies to date, administration of exendins and exendin agonists have not resulted in an increased incidence of hypoglycemia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
  • Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
  • Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Amidated Peptide Having SEQ ID NO. 9

[0175]The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole / g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. However, at some positions coupling was less efficient than expected and double couplings were required. In particular, residues Asp9, Thr7 and Phe6 all required double coupling. Deprotection (Fmoc group removal) of the growing peptide chain using piperidine was not always efficient. Double deprotection was required at positions Arg20, Val19 and Leu14. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction t...

example 2

Preparation of Peptide Having SEQ ID NO. 10

[0178]The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole / g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 25% to 75% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 21.5 minutes. Electrospray Mass Spectrometry (M): calculated 4168.6. found 4171.2.

EXAMPLE 3

Preparation of Peptide Having SEQ ID NO. 11

[0179]The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole / g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and pu...

example 3

Preparation of Peptide Having SEQ ID NO. 12

[0180]The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole / g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 65% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.7 minutes. Electrospray Mass Spectrometry (M): calculated 4212.6. found 4213.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
widthaaaaaaaaaa
concentrationsaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.

Description

RELATED APPLICATIONS[0001]This application is a continuation of co-pending U.S. application Ser. No. 10 / 342,014, filed on Jan. 13, 2003, which is a continuation Application of U.S. application Ser. No. 09 / 323,867, filed on Jun. 1, 1999, now U.S. Pat. No. 6,506,724.INCORPORATION OF SEQUENCE LISTING[0002]A paper copy of the Sequence Listing and a computer readable form of the sequence listing on diskette, containing the file named Seq.txt, which can be found in co-pending U.S. application Ser. No. 10 / 342,014 and which was created on May 7, 2003, are herein incorporated by reference.FIELD OF THE INVENTION[0003]The present invention relates to methods for treating gestational diabetes mellitus comprising administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other compounds or compositions that affect blood glucose control, such as an insulin or an amylin agonist. Pharmaceutical compositions for use in the methods of the invention are also...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/16A61P3/10A61K38/28A61K45/00A61K38/00A61K38/22
CPCY10S514/866A61K38/2278A61P3/10
Inventor HILES, RICHARD A.PRICKETT, KATHRYN S.
Owner ASTRAZENECA PHARMA LP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com